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Intramolecular hydrophobic 
interactions are critical mediators 
of STAT5 dimerization
Dirk Fahrenkamp1,*, Jinyu Li1,2,3,*, Sabrina Ernst1, Hildegard Schmitz-Van de Leur1, 
Nicolas Chatain4, Andrea Küster1, Steffen Koschmieder4, Bernhard Lüscher1, 
Giulia Rossetti3,4,5,† & Gerhard Müller-Newen1,†
STAT5 is an essential transcription factor in hematopoiesis, which is activated through tyrosine 
phosphorylation in response to cytokine stimulation. Constitutive activation of STAT5 is a hallmark of 
myeloid and lymphoblastic leukemia. Using homology modeling and molecular dynamics simulations, 
a model of the STAT5 phosphotyrosine-SH2 domain interface was generated providing first structural 
information on the activated STAT5 dimer including a sequence, for which no structural information 
is available for any of the STAT proteins. We identified a novel intramolecular interaction mediated 
through F706, adjacent to the phosphotyrosine motif, and a unique hydrophobic interface on the 
surface of the SH2 domain. Analysis of corresponding STAT5 mutants revealed that this interaction is 
dispensable for Epo receptor-mediated phosphorylation of STAT5 but essential for dimer formation 
and subsequent nuclear accumulation. Moreover, the herein presented model clarifies molecular 
mechanisms of recently discovered leukemic STAT5 mutants and will help to guide future drug 
development.
STAT5, represented by the highly homologous isoforms STAT5A and STAT5B, is an essential transcription factor 
for the proliferation, survival and differentiation of myeloid cells1. Hematopoietic cytokines such as erythropoie-
tin (Epo), thrombopoietin and GM-CSF activate Janus tyrosine kinases (JAKs) resulting in transient phosphoryl-
ation of STAT5 at a single conserved tyrosine residue (Y694 in STAT5A, Fig. 1a). Subsequently, STAT5 dimers are 
formed through reciprocal intermolecular phosphotyrosine-SH2 domain interactions. These dimers accumulate 
in the nucleus to induce target gene expression2,3. Persistently activated STAT5 has been observed in a variety of 
hematological disorders, including chronic (CML) and acute (AML) forms of myeloid leukemias4,5. Likewise, 
constitutive STAT5 signaling is associated with cKitD816V-positive systemic mastocytosis (SM)6,7 and several mye-
loproliferative neoplasms with mutated JAK2, MPL or calreticulin8. Importantly, STAT5 represents a vulnerable 
signaling node regulating tumor cell maintenance in the oncogenic networks of CML and AML cells, a fea-
ture known as non-oncogene addiction (NOA)4,9,10. Furthermore, the introduction of artificial gain-of-function 
mutants such as STAT5AS710F into mice identified STAT5 as a putative oncogene capable of inducing tumor initi-
ation in many hematopoietic cell types, independent of dysregulated upstream kinases11.
In addition to these functions in physiologic and malignant myelopoiesis, STAT5 represents a master regula-
tor of lymphopoiesis, controlling the proliferation and differentiation of T and B cells through various cytokines 
including IL-2 and IL-712,13. Accordingly, activating somatic mutations in the SH2 domain and the following 
C-terminal tail segment (CTS) of STAT5 (Fig. 1a) have been discovered in distinct types of T- and NK-cell lym-
phomas such as large granular lymphocytic leukemia (LGLL), acute T-cell leukemia (T-ALL) and T-cell prolym-
phocytic leukemia (T-PLL)14–19.
The addiction to STAT5-mediated signal transduction processes has been considered to be a potential Achilles 
heel in leukemic signaling networks, resulting in intense research aiming at the pharmacological inhibition of 
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Figure 1. MD simulations of the STAT5A dimer interface. (a) Multiple sequence alignment of STAT1, STAT3 
and STAT5A. SH2 domains and C-terminal tail segments (CTS) consisting of linker (L), phosphotyrosine 
motif (PTM) and the N-terminal part of the transactivation domain (nTAD) were aligned using the structure-
guided alignment mode of T-coffee56. Crystalized regions are marked with grey background. The conserved 
phosphorylation site for activation of STAT proteins is highlighted by a red dot. SH2 domain loops contributing 
to dimerization of STAT1 and STAT3 are depicted in blue and yellow boxes, respectively. Positions of disease-
related STAT5 mutations are indicated by asterisks. (b) Overlay of 20 frames (every 100 ns) of the MD 
simulations of the STAT5A dimer interface (top view). Grey: SH2 domains and L of monomer 1 (M1) and 
monomer 2 (M2). The PTM and nTAD (residues: 694–714) of monomers M1 and M2 are depicted in cyan 
and orange, respectively. (c) Most representative structure of the STAT5A dimer interface (top view) identified 
by cluster analysis over the equilibrated trajectories, ranging from 1500 ns to 2000 ns. SH2 domains and L are 
depicted as ribbon structures with transparent surface representation. PTM and nTAD are depicted as surface 
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STAT5. Hence, prevention of STAT5 dimer formation is thought to interfere with tumor cell proliferation and 
survival20–22. However, advances in this field have been hampered by the lack of structural information on the 
active STAT5 dimer, which could have indicated molecular interactions amenable to small molecule interference. 
To understand the mechanisms that promote constitutive activation of STAT5 mutants and to generate a template 
that may guide structure-based drug discovery, we generated a molecular model of the STAT5 dimer interface 
through homology modeling and molecular dynamics simulations. The model was validated by functional anal-
ysis of point mutants revealing the importance of a unique hydrophobic interface on the SH2 domain of STAT5 
for physiological as well as oncogenic activation of the transcription factor.
Results
Molecular dynamics simulation of the STAT5A dimer interface. Oncogenic somatic STAT5 muta-
tions are characterized by stimulation-independent activation and predominantly map to the SH2 domain 
(T628S, N642H, Y665F) of the transcription factor. However, constitutive STAT5 activation is additionally pro-
moted by somatic mutations located in the sequence following phosphotyrosine 694 (I699L, Q701L), a region for 
which only limited or no structural information is available for any of the STAT dimers (Fig. 1a).
Therefore, the structural determinants of the STAT5A dimer interface were predicted by bioinformatics 
approaches and molecular dynamics (MD) simulations. The modeled system includes the SH2 domain (residues 
589–687) and the C-terminal tail segment (CTS, res. 688–714), which consists of a short flexible linker 
(L, res. 688–693), the phosphotyrosine motif (PTM, res. 694–706) and the N-terminal part of the transactivation 
domain (nTAD, res. 707–714) (Fig. 1a). The initial model of the STAT5A active dimer interface was obtained 
by homology modeling. For the SH2 domain moiety the structure of the SH2 domain of inactive STAT5A23 as 
well as the available structures of the activated STAT1 and STAT3 dimers24,25 were used. Their SH2 domains 
share a very similar architecture with those of STAT5A with sequence identities of 30.8% and 34.2%, respectively 
(Supplementary Fig. 1a). For the CTS, which is not conserved across STAT proteins, we used templates other than 
STATs with sequence identities ranging from 26% to 37% (see Methods for more details).
Next, 2,000 ns-long MD simulations were performed (Fig. 1b) on the homology-based model of the active 
STAT5A dimer. Stability, sampling and convergence of the MD simulations were established by calculating the 
backbone root-mean-square deviation (RMSD) (Supplementary Fig. 1b). Hess analysis26 and RMSD both con-
firmed the adequate sampling of STAT5A conformations around the equilibrium position in the last 500 ns of 
the MD simulations (Supplementary Table 1). The most representative structure of the STAT5A dimer interface, 
covering more than half of the sampled conformations, was identified by cluster analysis (Fig. 1c). Superposition 
of our representative structure of the STAT5A SH2 domain revealed a high structural similarity with the crystal-
ized SH2 domains of STAT1, STAT3 and inactivated STAT5A23–25 demonstrated by low backbone RMSD values 
(< 0.2 nm) (Fig. 1d and Supplementary Fig. 1c). According to our model and in analogy to the crystal structures 
of activated STAT1 and STAT3 dimers, the dimerization of STAT5A is established by three distinct interfaces, 
involving reciprocal intermolecular PTM-SH2 domain interactions (1), intermolecular PTM-PTM interactions 
(2) and intramolecular PTM-SH2 domain interactions (3) (Fig. 1e). The first interface is characterized by the 
classical phosphotyrosine-SH2 domain interaction present in all activated STAT dimers, whereas the second and 
third interfaces are substantially different from those of STAT1 and STAT3. The latter indeed feature a flexible 
loop structure, which significantly contributes to the dimerization by providing a stabilizing framework for the 
percolating PTM (blue and yellow loops in Fig. 1f). Interestingly, the residues belonging to this loop-structure 
are not conserved in the SH2 domain of STAT5 proteins (blue and yellow boxes in Fig. 1a). Hence, the MD sim-
ulations suggest that the dimerization interface established by STAT5 proteins is different from those of STAT1 
and STAT3.
SH2 domain mediated STAT5 dimerization. In STAT5A, the phosphorylated tyrosine (pY694) in the 
CTS of monomer 1 (M1) interacts with the SH2 domain of the opposite monomer (M2) in a direction orthogonal 
to the strands of the central β -sheet (Fig. 2a). In a symmetric fashion, also pY694 in the CTS of M2 (pY694M2) 
interacts with the SH2 domain of M1 with the same orientation as pY694M1. Salt bridges formed by pY694 and 
the highly conserved and invariant R618 located in the β B strand of the opposite SH2 domain are key interactions 
in both intermolecular PTM-SH2 domain interfaces. Indeed, they are fully preserved during the MD simulations 
with occupancies of 100% (pY694M1) and 97% (pY694M2), respectively. Moreover, the coordination of pY694 in 
both monomers is supported by the formation of transient hydrogen bond interactions with K600, S620, S622 
and T628 in the opposite monomer during the MD simulations (Fig. 2a and Supplementary Table 2). Notably, 
these residues are conserved in all STAT family members and have been described to be involved in the formation 
representation. Cyan: M1, orange: M2. (d) Superposition and root-mean-square deviation (RMSD) values 
between the most representative model of the activated STAT5A SH2 domain (M2, orange) and the SH2 
domains of the crystal structures of activated STAT1 (pink)/STAT3 (blue) and inactivated (*) STAT5A (cyan) 
23–25. (e) Cartoon of the STAT5A dimer interface. Interactions are established by three distinct interfaces 
involving intermolecular PTM-SH2 domain interactions (1), intermolecular PTM-PTM interactions (2) and 
intramolecular PTM-SH2 domain interactions (3). M1 and M2 are depicted cyan and orange, respectively.  
(f) Switch from inter- to intramolecular interactions in SH2 domain interfaces of STAT1, STAT3 and STAT5A 
(side view). SH2 domains are depicted as surface representation (grey) with SH2 domain loops colored in blue 
(STAT1) and yellow (STAT3) (compare Fig. 1a). The course of a single PTM of each dimer interface is shown in 
stick representation (green). Atoms color code: Green, carbon; red, oxygen; blue, nitrogen; orange, phosphorus; 
yellow, sulfur.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:35454 | DOI: 10.1038/srep35454
Figure 2. The phosphotyrosine-SH2 domain interface of STAT5A. (a) STAT5A dimer interface (top view). 
The SH2 domains are depicted in surface representation colored in grey, while the C-terminal part of the L, 
the PTM and the nTAD are shown as ribbon structure in cyan (M1) and orange (M2). The phosphotyrosine 
acceptor interfaces are highlighted in cyan (M1) and orange (M2). The side chain of pY694 is shown in stick 
representation. A magnification of the phosphotyrosine-SH2 domain interaction is shown for both interfaces. 
Selected residues are shown in stick representation. Side chains involved in pY694 coordination are depicted 
in magenta (carbon). Red, oxygen; blue, nitrogen; white, phosphorus. Residue labels are colored in cyan or 
www.nature.com/scientificreports/
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of hydrogen bonds in phosphotyrosine-SH2 domain interfaces of STAT1 and STAT3 (Supplementary Fig. 2 and 
Supplementary Table 3)24,25.
Our model further identified two novel residues involved in the recognition of pY694. These are the β D res-
idues N642 (β D5) and K644 (β D7), which stabilize the aromatic ring of the phosphotyrosine by hydrophobic 
interactions (Fig. 2b and Supplementary Fig. 2). Finally, V695 (pY+ 1) packs into a hydrophobic pocket of the 
opposite monomer containing W631, W641 and L643, consistently to what has been observed in the structures 
of STAT1 and STAT324,25 (Fig. 2c and Supplementary Fig. 2). We therefore conclude that our model of STAT5A 
correctly reproduces the conserved intermolecular PTM-SH2 domain contacts of known STAT dimer interfaces 
involving residues conserved across the family and at the same time reveals STAT5-specific interactions.
In addition to the PTM-SH2 domain interface, intermolecular interactions are observed between the 
C-terminal parts of the PTMs, allowing the recognition of each PTM by the opposite monomer over a length of 
11 residues subsequent to phosphotyrosine. In contrast to the STAT1/STAT3 crystal structures, the PTM-PTM 
interface in our model is structurally disordered and constituted by non-conserved moieties. Although most of 
the interactions are transiently established due to the disordered nature of the two moieties, a distinct network 
of intermolecular hydrogen bonds was identified: this involves Q698M1 and K700M1 with Q701M2, and I699M2 
and Q698M2 with E705M1 (Fig. 2d and Supplementary Table 4). Additionally, hydrophobic contacts between 
the side chains of P697M1 and V702M2, and between those of V702M1 and I699M2 were identified (Fig. 2d and 
Supplementary Table 5). Of note, residues in the pY+ 3 (P697), pY+ 5 (I699) and pY+ 7 (Q701) position ulti-
mately define the shape of the PTM-PTM interface in STAT1 and STAT3 dimers.
Intramolecular PTM-SH2 domain interactions: a hydrophobic interface in the SH2 STAT5 
domain is critical for dimerization. In addition to the intermolecular interactions, our model revealed 
intramolecular contacts between the PTM and a hydrophobic interface in the SH2 domain that might play a fun-
damental role in the dimerization of STAT5A. In particular, F706 located in the very C-terminal part of the PTM 
establishes interactions with W631, F633, W641, L663, Y665 and L666 of its cognate SH2 domain (Fig. 3a,b and 
Supplementary Fig. 3). Specifically, the MD simulations revealed that F706M1 forms aromatic interactions mainly 
with F633M1 and W641M1, as shown by their large persistence of 55.1% and 60.0% during the simulation time 
(Supplementary Table 6) and transient ones with W631M1 (5.4% of persistence). In the opposite monomer, F706M2 
forms aromatic interactions with F633M2, Y665M2 and W631M2 with occupancies of the hydrophobic contacts of 
41.4%, 41.3% and 21.7%, respectively. Such a network of hydrophobic interactions substantially contributes to 
the recognition of F706 in their respective interfaces (Supplementary Table 6). The involved residues are not con-
served across the STAT family indicating a candidate interface to target STAT5 specifically.
The relevance of the observed intramolecular hydrophobic interactions for STAT5A function was evaluated by 
assessing the Epo receptor (EpoR)/JAK2-mediated phosphorylation of Y694, dimer formation and nuclear accu-
mulation of STAT5A being mutated at residue F706 (F706A) or in the hydrophobic acceptor interface (F633A, 
W641A and Y665A). These mutants were studied in comparison to STAT5A wild-type and the non-functional 
R618Q mutant. HeLa T-REx cells stably expressing eYFP-tagged STAT5A constructs and the EpoR revealed 
a severely impaired tyrosine phosphorylation of all mutants in response to Epo stimulation. Intriguingly, 
the inhibition of phosphatases by sodium vanadate treatment rescued the Epo-induced phosphorylation of 
STAT5A mutants F706A, F633A or Y665A demonstrating that the reduced phosphorylation of these mutants 
in the absence of vanadate is caused by phosphatase activity rather than dysfunctional receptor recruitment 
(Fig. 3c). Of note, vanadate treatment alone did not result in phosphorylation of any of the STAT5A constructs 
(Supplementary Fig. 4).
To study the impact of these mutations on STAT5A dimerization, blue-native PAGE was performed. Since 
phosphorylation at Y694 is a prerequisite for the formation of STAT5A dimers, lysates were analyzed after treat-
ment of cells with Epo and vanadate. Phosphatase inhibition resulted in a 2.15-fold increase in dimerization of 
STAT5A wild-type in response to Epo stimulation, illustrating that the EpoR/JAK2/STAT5A signaling pathway 
in steady-state is highly counter-regulated by phosphatases. Surprisingly, while in response to vanadate treatment 
STAT5A proteins carrying the F706A mutation appeared to be phosphorylated markedly above reference levels 
(Epo stimulation of STAT5A wild-type in the absence of vanadate), their dimerization was severely impaired 
(− 2.37-fold) (Fig. 3d,e). Likewise, the mutations F633A (− 1.59-fold) and Y665A (− 2.07-fold) located in hydro-
phobic interface of the SH2 domain, compromised dimerization, indicating that the intramolecular interaction 
between F706 and the hydrophobic interface is essential for dimerization of tyrosine-phosphorylated STAT5A 
and probably to maintain the phosphate by shielding it from phosphatases (Fig. 3d,e).
orange according to the corresponding monomer. Hydrogen bonds are indicated by dashed lines (See also 
Supplementary Fig. 2 and Supplementary Table 2). (b) Magnification of the hydrophobic phosphotyrosine-SH2 
domain interactions in M2. Residues involved in the coordination of phosphotyrosine 694 are shown in stick 
representation. N642 and K644 form direct hydrophobic contacts with the phenyl ring of phosphotyrosine. 
D621 localizes in close proximity to the phosphate group. The coloring scheme is the same as in (a). (See also 
Supplementary Fig. 2 and Supplementary Table 2). (c) Magnification of the V695-binding interface (pY+1) 
in the SH2 domain of M2. Residues forming hydrophobic contacts (W631, W641 and L643) with V695 are 
highlighted in stick representation. The coloring scheme is the same as in (a). (See also Supplementary Fig. 2). 
(d) Schematic, 2D representation of the STAT5A PTM-PTM interface generated by the LIGPLOT+ package57. 
Hydrophobic interactions (red, M1; pink, M2) and hydrogen bonds are indicated by spokes and dashed green 
lines, respectively. The residues forming hydrogen bonds are shown by ball-and-stick representations (cyan, M1; 
orange, M2).
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Figure 3. A hydrophobic interaction in the STAT5A SH2 domain is critical for dimerization. (a) STAT5A 
dimer interface (top view). The SH2 domains are depicted in surface representation (grey). The hydrophobic 
interfaces containing W631, F633, W641, L663, Y665 and L666 are highlighted in cyan (M1) and orange (M2). 
Both CTSs are depicted as ribbon structures. Side chains of pY694 and F706 are shown in stick representation. 
Magenta, carbon; red, oxygen; white, phosphorus. (b) Magnification of the hydrophobic interfaces in both 
monomers (cyan, M1; orange, M2). Residues of the hydrophobic interface and F706 (carbon magenta) 
are shown in stick representation. (c) Y694 phosphorylation of STAT5A-eYFP or STAT5A mutants stably 
www.nature.com/scientificreports/
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In contrast, vanadate treatment failed to restore the receptor-mediated phosphorylation of the STAT5A 
mutants F633A/Y665A, W641A and R618Q to reference levels (Fig. 3c–e), suggesting that these muta-
tions severely affect the structural integrity of the SH2 domain and thus prevent appropriate recruitment to 
signaling-competent receptors.
In resting cells, STAT5 is evenly distributed between cytoplasm and nucleus. Formation of phosphoryl-
ated dimers is a requirement for nuclear accumulation of STAT5. Confocal imaging of fluorescently labeled 
STAT5A revealed that vanadate treatment resulted in a forced nuclear enrichment of the wild-type protein in 
erythropoietin-stimulated cells, while the investigated STAT5A mutants did not accumulate in the nucleus 
reflecting their impaired capability to form dimers (Fig. 3f). Taken together the data demonstrated that F706, an 
aromatic residue located in a region for which no structural information is available for any of the STAT proteins, 
is essential for the formation of activated STAT5A dimers. Moreover, tyrosine phosphorylated monomers that fail 
to dimerize undergo rapid dephosphorylation.
Disease mutations N642H and T628S in the phosphotyrosine-SH2 domain interface improve 
phosphotyrosine-binding but require F706. In a defined subset of aggressive lymphoid cancers, 
the somatic mutations N642H (β D5) and T628S (β -sheet C) have recently been identified, which map to the 
phosphotyrosine-binding pocket in interface 1 of the STAT5 SH2 domain (Figs 1e, and 4b). In particular, the 
N642H mutation was found at high frequencies in lymphomas of NK or γ δ T-cell origin and in T-cell prolym-
phocytic leukemia (T-PLL) patients with high frequencies of 33.3% (7/21), 14.9% (14/94) and 22.0% (11/50), 
respectively15,17,19. Moreover, N642H mutations were detected at lower frequencies in T-cell acute lymphoblastic 
leukemia (T-ALL), pediatric T-ALL and fatal large granular lymphocytic leukemia (LGLL) (7.4% (5/68), 6.3% 
(19/301) and 1.9% (4/211), respectively)14,16,18. The T628S mutation was found at a frequency of 6.0% (3/50) in 
T-PLL patients15.
Peptide precipitation experiments using a peptide containing phosphorylated Y694 revealed that these muta-
tions increase the binding affinity of the mutated SH2 domains to the phosphotyrosine motif (Fig. 4b). Blue-native 
PAGE analyses further confirmed the activating phenotype of STAT5AN642H and STAT5AT628S by the detection of 
dimers that appeared 2.10-fold and 1.48-fold increased in Epo-stimulated cells, suggesting that both mutations 
interfere with appropriate deactivation of the JAK-STAT signaling pathway (Fig. 4c,d). Moreover, STAT5AN642H 
dimers appeared already considerably elevated in the absence of stimulation (1.27-fold) demonstrating that this 
mutation confers a stronger constitutive activation to STAT5 proteins compared to T628S (Fig. 4c,d).
Interestingly, the combination of activating N642H and T628S mutations with F706A resulted in significantly 
diminished STAT5A dimer levels in Epo-stimulated cells with fold changes of − 2.47 and − 4.51, respectively. 
Moreover, the dimerization of both double mutants appeared significantly impaired in vanadate treated cells 
compared to their single mutated counterparts (4.26-fold and 2.70-fold). Strikingly, phosphatase inhibition failed 
to restore STAT5A dimerization back to reference levels confirming that the phosphorylation of STAT5A is nec-
essary yet not sufficient for dimerization (Fig. 4c,d). These findings identify interface 3 as a target region for the 
development of compounds against activating STAT5 mutations implicated in aggressive lymphoid cancers with 
poor prognosis.
Mutations in the PTM-PTM interface enhance STAT5 dimerization. Compared to the N642H 
mutation, the I699L mutation (I704L in STAT5B) appears at a lower frequency of 2.0% in lymphomas of NK 
or γδ T-cell origin (1/94)17 and T-ALL patients (1/68)16. Likewise, the Q701L mutation (Q706L in STAT5B) is 
present at a frequency of 2.0% (1/50)15 in T-PLL patients. I699 and Q701 map to the PTM at positions pY+5 and 
pY+7, respectively. Here, we analyzed the impact of these substitutions on STAT5A function in order to verify the 
relevance of intermolecular PTM-PTM contacts for dimerization (Fig. 5a). Blue-native PAGE analyses revealed 
an activating phenotype of both mutations in stimulated cells with an increase in dimerization of 1.96-fold and 
1.43-fold compared to wild-type (Fig. 5b,c). In contrast to STAT5N642H, mutations in the PTM resulted only in 
a weak factor-independent constitutive activation, illustrating that both mutants are more sensitive to dephos-
phorylation similar to STAT5AT628S. The introduction of the F706A mutation into I699L and Q701L mutants 
again significantly diminished dimerization in stimulated cells compared to the corresponding single mutants 
expressed in HeLa T-REx HA-EpoR cells treated with sodium vanadate (1 mM, 1.5 h) as indicated. Cells were 
stimulated with 1 U/ml Epo for 30 min or left unstimulated. Whole cellular lysates (WCLs) were subjected 
to immunoblotting using antibodies against pY694/699-STAT5A/B and GFP. This blot and the following 
blots and gels were cropped to focus on relevant bands. The full-length blots and gels are provided with 
the Supplementary Information. (d) Native PAGE analysis of WCLs of HeLa T-REx HA-EpoR cells stably 
expressing STAT5A-eYFP or STAT5A mutants, treated with sodium vanadate (1 mM, 1.5 h) and/or Epo  
(1 U/ml, 30 min) as indicated. The native gel was analyzed by fluorescence scanning for the detection of YFP-
tagged proteins. WCLs were subjected to immunoblotting using antibodies against pY694/699-STAT5A/B and 
GFP. (e) Quantification of native PAGE experiments. Normalized STAT5A dimerization levels and normalized 
pSTAT5/STAT5A ratios relative to stimulated cells expressing wild-type STAT5A were plotted. The data shown 
represent geometric means ± 95% confidence intervals of n = 4 independent experiments statistically evaluated 
by a paired ratio t-test with ***p < 0.005, **p < 0.01 and *p < 0.05. (f) Effect of sodium vanadate (V) treatment 
(1 mM, 1.5 h) on the nuclear accumulation of STAT5A-eYFP (yellow) and the indicated mutants in Epo-
stimulated (1 U/ml, 30 min) HeLa T-REx HA-EpoR cells. Nuclei (blue) and the actin cytoskeleton (red) were 
stained with DRAQ5 and phalloidin, respectively. Unstimulated and Epo-stimulated cells served as controls 
(upper panel, left and middle). Scale bars: 20 μ m.
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(3.13-fold and 2.54-fold), despite boosted phosphorylation levels caused by vanadate treatment (Fig. 5b,c). 
Without phosphatase inhibition Y694 phosphorylation was markedly reduced (Supplementary Fig. 5). Notably, 
each of both double mutants partially rescued the dimerization defect of STAT5AF706A, suggesting that stabilizing 
intermolecular interactions in the PTM-PTM interface increase dimer stability, interfere with appropriate inacti-
vation through STAT5-specific phosphatases and partially compensate for the loss of F706 (Fig. 5b). Nevertheless, 
Figure 4. STAT5A mutations N642H and T628S cause constitutive activation and remain susceptible to 
F706 substitution. (a) STAT5A dimer interface. Monomer 1 is depicted as ribbon structure (cyan). The SH2 
domain of monomer 2 is shown in surface representation (grey) with the CTS (res. 690–707) depicted as ribbon 
structure (orange). Side chains of pY694 and F706 are shown in stick representation. Magenta, carbon; red, 
oxygen; white, phosphorus. The phosphotyrosine-SH2 domain interface is magnified and residues contributing 
to phosphotyrosine-binding are shown in stick representation and orange surface color. Mutation-sites 
N642 and T628 are highlighted in magenta. (b) Peptide precipitation assay using WCLs of HeLa T-REx FRT 
cells expressing STAT5A-eYFP, STAT5AN642H-eYFP or STAT5AT628S-eYFP. Lysates were incubated with 
biotinylated control (F694) or phosphorylated (pY694) STAT5A peptides coupled to NeutrAvidin-Agarose. 
Precipitates and WCLs were analyzed by immunoblotting using a GFP-specific antibody. (c) Native PAGE 
analysis of WCLs of HeLa T-REx HA-EpoR cells stably expressing STAT5A-eYFP or STAT5A mutants, treated 
with sodium vanadate (1 mM, 1.5 h) and/or Epo (1 U/ml, 30 min) as indicated. The native gel was analyzed by 
fluorescence scanning for the detection of YFP-tagged proteins. WCLs were subjected to immunoblotting using 
antibodies against pY694/699-STAT5A/B and GFP. (d) Quantification of native PAGE experiments. Normalized 
STAT5A dimerization levels and normalized pSTAT5/STAT5A ratios relative to stimulated cells expressing 
wild-type STAT5A were plotted. The data shown represent geometric means ± 95% confidence intervals of 
n = 4 independent experiments statistically evaluated by a paired ratio t-test with ***p < 0.005, **p < 0.01 and 
*p < 0.05.
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phosphorylation kinetics revealed that the mutation of F706 to alanine effectively abolishes constitutive activation 
of STAT5AI699L and STAT5AQ701L in stimulated cells (Fig. 5d).
Constitutive STAT5 activation by the Y665F mutation in the hydrophobic interface. The Y665F 
mutation has been identified in T-PLL, NK/γ δ T-cell lymphomas, T-ALL and LGLL with frequencies of 6.0% 
Figure 5. PTM mutations I699L and Q701L convey constitutive STAT5 activation through increased 
intermolecular PTM-PTM contacts. (a) STAT5A dimer interface (top view). The SH2 domains are depicted 
in surface representation (grey). The hydrophobic interfaces are highlighted in cyan (M1) and orange (M2), 
respectively. Both CTSs are depicted as ribbon structures. Side chains of pY694, I699, Q701 and F706 are 
shown in stick representation. Magenta, carbon; red, oxygen; white, phosphorus. The PTM-PTM interface is 
magnified and residues I699 and Q701 of both monomers are shown in stick representation. (b) Native PAGE 
analysis of WCLs of HeLa T-REx HA-EpoR cells stably expressing STAT5A-eYFP or STAT5A mutants, treated 
with sodium vanadate (1 mM, 1.5 h) and/or Epo (1 U/ml, 30 min) as indicated. The native gel was analyzed by 
fluorescence scanning for the detection of YFP-tagged proteins. WCLs were subjected to immunoblotting using 
antibodies against pY694/699-STAT5A/B and GFP. (c) Quantification of native PAGE experiments. Normalized 
STAT5A dimerization levels and normalized pSTAT5/STAT5A ratios relative to stimulated cells expressing 
wild-type STAT5A were plotted. The data shown represent geometric means ± 95% confidence intervals of 
n = 3 independent experiments statistically evaluated by a paired ratio t-test with ***p < 0.005, **p < 0.01 and 
*p < 0.05. (d) Tyrosine 694 phosphorylation kinetics of STAT5A-eYFP or the indicated STAT5A mutants stably 
expressed in HeLa T-REx HA-EpoR cells. Cells were pulse-stimulated with 1 U/ml Epo for 30 min and analyzed 
at the indicated time periods. WCLs were subjected to immunoblotting using antibodies against pY694/699-
STAT5A/B and GFP.
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(3/50)15, 2.1% (2/94)17, 1.5% (1/68)16 and 1% (2/211)18, respectively. Y665 is part of the hydrophobic acceptor 
interface for the intramolecular recognition of F706 in wild-type STAT5A (Fig. 6a). STAT5AY665F showed a sig-
nificant 1.82-fold (p = 0.0020) increase in the amount of dimers in stimulated cells compared to reference levels, 
while vanadate treatment remained again insufficient to rescue pSTAT5AF706A or pSTAT5AF706G dimerization 
(Fig. 6b,c).
Figure 6. F706 is required for constitutive activity of the Y665F mutation. (a) STAT5A dimer interface 
(top view). The SH2 domains are depicted in ribbon (cyan, M1) or surface representation (grey, M2). The 
hydrophobic interface of M2 is highlighted in orange. Both CTSs are depicted as ribbon structures. Side chains 
of pY694, I699 and F706 are shown in stick representation. Magenta, carbon; red, oxygen; white, phosphorus. 
The F706 interface is magnified and residues F706, L663, Y665, F633, L666 and W631 are shown in stick 
representation. Mutation-site Y665 is highlighted in magenta. (b) Native PAGE analysis of WCLs of HeLa 
T-REx HA-EpoR cells stably expressing STAT5A-eYFP or STAT5A mutants, treated with sodium vanadate 
(1 mM, 1.5 h) and/or Epo (1 U/ml, 30 min) as indicated. The native gel was analyzed by fluorescence scanning 
for the detection of YFP-tagged proteins. WCLs were subjected to immunoblotting using antibodies against 
pY694/699-STAT5A/B and GFP. (c) Quantification of native PAGE experiments. Normalized STAT5A 
dimerization levels and normalized pSTAT5/STAT5A ratios relative to stimulated cells expressing wild-
type STAT5A were plotted. The data shown represent geometric means ± 95% confidence intervals of n = 3 
independent experiments statistically evaluated by a paired ratio t-test with ***p < 0.005, **p < 0.01 and 
*p < 0.05. (d) Tyrosine 694 phosphorylation kinetics of STAT5A-eYFP or the indicated STAT5A mutants stably 
expressed in HeLa T-REx HA-EpoR cells. Cells were pulse-stimulated with 1 U/ml Epo for 30 min and analyzed 
at the indicated time periods. WCLs were subjected to immunoblotting using antibodies against pY694/699-
STAT5A/B and GFP.
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Similar to intermolecular disease mutations in the PTM-SH2 domain and PTM-PTM interfaces, upon 
combination of Y665F with either F706A or F706G dimers were hardly detectable with significant reductions 
of 5.94-fold (p = 0.0003) and 6.16-fold (p = 0.0007) in stimulated cells compared to the Y665F single mutant 
(Fig. 6b,c). Surprisingly, the inhibition of phosphatase activity by vanadate efficiently rescued the dimerization 
of STAT5AY665F carrying the F706A (3.90-fold) or F706G (3.50-fold) mutation, suggesting that the elimination of 
the Y665-hydroxyl group is sufficient to enable appropriate dimerization of STAT5AF706A/G. Nevertheless, these 
dimers remained highly susceptible for phosphatases. Therefore, it appears evident that besides its role in the 
dimerization process, binding of F706 to the hydrophobic interface is critical to protect STAT5A dimers from 
rapid inactivation (Fig. 6b,c). In accordance with this concept, phosphorylation kinetics of both double mutants 
confirmed a phenotype comparable to wild-type STAT5A (Fig. 6d).
Discussion
The crystal structures of the activated STAT1 and STAT3 dimers were used to predict the structural determinants 
of the fully assembled SH2 domain interface of STAT5A by the combination of homology modeling and MD 
simulations. The resulting model, validated with experimental data, revealed novel and unique features of the 
dimerization interface of STAT5A and was used to unravel the impact of disease-related STAT5 mutations on 
protein structure and function.
Not unexpected, the model corroborates reciprocal phosphotyrosine-SH2 domain interactions as a conserved 
driver of STAT dimerization resulting in a grossly symmetric dimer24,25. However, by comparing the contribu-
tion of individual residues to the coordination of the phosphotyrosine residue in each of both interfaces, a local 
structural asymmetry was observed (Fig. 2). Likewise, MD simulations of STAT1 and STAT3 dimers, which were 
generated based on their corresponding crystal structures, identified large-scale motions of both dimers finally 
resulting in non-symmetric interfaces27. In general, local asymmetry in otherwise symmetric protein complexes 
is not unusual28,29. In STAT5A, such asymmetry might mirror the transient nature of the phosphotyrosine-SH2 
domain interaction that has evolved for temporary release of the phosphotyrosine moiety to become accessible 
for dephosphorylation30.
The binding interface selectivity of SH2 domains is mediated by individual binding pockets, additional to 
the phosphotyrosine-binding site, that primarily recognize residues in the pY+ 1 and pY+ 3 positions located 
C-terminal to the phosphotyrosine residue. In most SH2 domains, the β D5 residue critically contributes to selec-
tivity by recognition of the pY+ 1 position31,32. Surprisingly, in the dimer structures of STAT1 and STAT3, the βD5 
residue (A630 and S636) coordinates the phenyl ring of phosphotyrosine by providing non-polar interactions 
rather than accepting the pY+ 1 residue24,33. An equal binding mode with N642 located in the β D5 position is 
preserved in the STAT5A simulation (Fig. 2b and Supplementary Table 3). Intriguingly, while electrostatic con-
tacts established by threonine in the pY+ 3 position were conserved between STAT1 and STAT3, the presence of 
proline at the corresponding position in the PTM of STAT5A prevents a similar binding mode, indicating that 
the recognition of the pY+ 3 residue by STAT SH2 domains might serve as a first step to define binding interface 
selectivity.
In STAT1 and STAT3, the PTM forms a pair of cross-over connections with the opposite PTM significantly 
increasing the intermolecular contact area at the dimer interface24,25. These intermolecular PTM-PTM interac-
tions were also present in the simulation of the STAT5A dimer interface (Fig. 2d). In STAT1 and STAT3, these 
interactions are predominantly mediated by residues located in loops present in the SH2 domain finally estab-
lishing a clamp-like architecture. The resulting tunnel-like arrangement provides structural guidance for the per-
colating PTM (Fig. 1f). The lack of these loops in STAT5A is compensated by a hydrophobic interface in the 
SH2 domain that functions as an intramolecular acceptor of F706 located in the PTM of STAT5A (Fig. 3a,b). 
Consequently, mutations of either donor (F706) or acceptor (F633, Y665) residues severely impaired the dimer-
ization and subsequent nuclear accumulation of pSTAT5A, demonstrating that intramolecular interactions are 
indeed indispensable for appropriate dimerization.
In recent years, an increasing number of somatic STAT5 mutations has been identified in leukemia patients. 
The vast majority of lymphoma-associated STAT5 mutations such as N642H, T628S, I699L, Q701L and Y665F 
map to the SH2 domain and PTM of the transcription factor and are characterized by an activating phenotype14–19.
The mutations N642H and T628S reside in the phosphotyrosine-binding interface and peptide precipita-
tions confirmed an increased binding affinity for both of the mutated SH2 domains suggesting that constitutive 
activity is a consequence of an impaired inactivation by STAT5 phosphatases (Fig. 4b,e). MD simulation data 
revealed that N642 contributes to the coordination of the phenyl ring of phosphotyrosine by providing non-polar 
contacts. Consequently, it is tempting to speculate that the substitution of the amide side chain of asparagine 
by an imidazole group stabilizes phosphotyrosine through a π -stacking mechanism17,34,35. Alternatively, hydro-
gen bond interactions formed between the NH-group of the imidazole side chain and phosphotyrosine might 
result in an increased affinity between the interaction partners (Fig. 2b, Supplementary Table 2). Likewise, T628 
was identified to support phosphotyrosine recognition through the formation of hydrogen bond interactions 
(Fig. 2a, Supplementary Table 2). Conceivably, the substitution of the threonine methyl group by hydrogen in 
STAT5AT628S directly strengthens phosphotyrosine coordination by the SH2 domain. Importantly, the improved 
phosphotyrosine-binding ability of both SH2 domains did not suffice to rescue dimerization of STAT5A pro-
teins lacking F706, further strengthening the relevance of intramolecular interactions for STAT dimerization 
(Fig. 4c,d).
In addition to phosphotyrosine-SH2 domain interactions, intermolecular contacts between the two PTMs 
have been reported to be important mediators for the dimerization of STAT1 and STAT324,25. In support of this 
concept, our data showed that the cancer-related activating mutations I699L and Q701L located in interface 
2 of the STAT5A molecule indeed resulted in elevated dimerization levels, but remained highly susceptible to 
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alteration of the F706 residue (Fig. 5c,d). Notably, STAT5AI699L/F706A and STAT5AQ701L/F706A exhibited a weaker 
dimerization defect compared to the F706A mutant providing evidence that L699 (pY+ 5) and L701 (pY+ 7) sig-
nificantly support the dimerization of STAT5A. Hence, constitutive activation of STAT5AI699L and STAT5AQ701L 
is most likely a consequence of increased binding affinities between the two PTMs (Fig. 5c,d). Accordingly, muta-
tion of I699 to alanine results in accelerated dephosphorylation of STAT5A (data not shown).
Finally, while intramolecular interactions of the PTM with the SH2 domain exist in STAT1 and STAT324,25, 
their contribution to the dimerization process has not yet been addressed. Based on our simulation data, it 
appears conceivable that constitutive activity of STAT5AY665F is caused by increased intramolecular binding of 
F706. Blue-native PAGE analyses indeed demonstrated that STAT5AF706A/G proteins carrying the Y665F mutation 
in the hydrophobic acceptor interface became highly susceptible to phosphatase activity and thus confirm the 
relevance of F706 in protecting STAT5A dimers from excessive deactivation (Fig. 6b,c).
Surprisingly, these experiments additionally revealed that F706A and F706G mutations only moderately com-
promised the dimerization potential of STAT5AY665F, indicating that the Y665F mutation compensates the dimer-
ization defect of STAT5AF706A/G. Possibly, F706 itself orchestrates the orientation of the aromatic components 
located in the hydrophobic pocket to allow for dimerization of STAT5A.
Conclusively, the data demonstrated that the presence of F706 is critical for the dimerization process of phos-
phorylated STAT5A. Additionally, the hydrophobic interactions protect the STAT5A dimer from rapid inacti-
vation by phosphatases. In the light of the fact that the VHR phosphatase utilizes a phosphotyrosine motif to 
displace the PTM from the STAT5A SH2 domain, increased binding affinities in all three interfaces suffice to 
interfere with this particular mechanism and render STAT5 proteins constitutively active36. Elumalai and col-
leagues recently reported on the development of the STAT5 inhibitor Stafib-1 that might simultaneously engage 
the phosphotyrosine binding pocket and the hydrophobic interface37. Our study gives a rational explanation for 
the action of this inhibitor and strongly supports the notion that the pharmacological inhibition of F706-binding 
to the hydrophobic interface in combination with compounds occupying the phosphotyrosine-binding pocket in 
the SH2 domain, represents a promising strategy to develop potent and selective STAT5 inhibitors.
Methods
Homology modeling. The structural determinants of activated STAT5A dimer interface (residues 589–714, 
SH2 domain + CTS) were initially obtained by using homology modeling. The latter was based on the corre-
spondent domains in the crystal structures of activated STAT1 dimer (PDB ID: 1BF525), activated STAT3 dimer 
(PDB ID: 1BG124), and inactive STAT5A monomer (PDB ID: 1Y1U23) (sequence identities 25.5%, 31.9%, and 
100%, respectively). Additional templates were identified for the highly disordered nTAD domain by the BLAST 
webserver (http://blast.ncbi.nlm.nih.gov/Blast.cgi). These are bacteria CobB sirtuin (residues 260–266 of PDB ID: 
1S5P38) and Parkia platycephala lectin 2 (residues 227–231 and 234–241 of PDB ID: 2GSJ39), with sequence iden-
tities of 26% and 37%, respectively. 200 models of the dimer were generated using the MODELLER 9v9 package40. 
They turned out to have 80% residues or more in the most favored regions of Ramachandran plots41, as shown 
by the Procheck program42. Specifically, the structures of activated STAT1 and STAT3 dimers were used only to 
retrieve the initial dimerization patterns of the STAT5A SH2 domain dimer.
Molecular dynamics simulation. The homology model with the lowest DOPE (discrete optimized protein 
energy) scoring function43 as implemented in MODELLER was inserted into a water box with edge lengths of 
64 Å, 73 Å and 84 Å. The protonation states of histidine residues (H604 of each monomer) were assigned to Nε 
nitrogen atom protonated according to the corresponding pKa values calculated by using the H++ webserver44. 
The system was neutralized by Na+ ions. Including water molecules, the system overall contained 39,901 atoms. 
It underwent MD simulations with AMBER ff99SB-ILDN force field45–48 using the GROMACS 4.6.5 code49. The 
Åqvist potential50 and TIP3P model51 were used for the ions and for the water molecules, respectively. All bond 
lengths were constrained by LINCS algorithm52. Periodic boundary conditions were applied. Electrostatic inter-
actions were calculated using the Particle Mesh-Ewald (PME) method53, and van der Waals and Coulomb interac-
tions were truncated at 1.0 nm. The system underwent 1,000 steps of steepest-descent energy minimization with 
1,000 kJ·mol− 1 Å− 2 harmonic position restraints on the protein, followed by 2,500 steps of steepest-descent and 
2,500 steps of conjugate-gradient minimization without restraints. The system was then gradually heated from 0 K 
up to 298 K in 20 steps of 2 ns. After that, 2000 ns long productive MD simulations were carried out in the NPT 
ensemble. The most representative structure was identified by the cluster analysis49 over the equilibrated trajec-
tories, ranging from 1500 ns to 2000 ns. To assess the convergence of the simulated trajectory we considered their 
projections on the top essential dynamical spaces obtained from a standard covariance analysis. Following Hess’s 
criterion26, these projections were next compared with those expected for a random reference. The observed neg-
ligible overlap (i.e. cosine content close to 0, see Supplementary Table 1) confirms a posteriori adequate sampling 
of STAT5A conformations around the equilibrium position in the last 500 ns. Hydrogen bond interactions were 
defined to be present if the atomic distance between the acceptor and donor atoms is below 0.35 nm and the angle 
among the hydrogen-donor-acceptor atoms are below 30 degree. Hydrophobic interactions were defined to be 
present if the center-of-mass distance between side chains are smaller than 0.5 nm54.
Hormones and antibodies. Erythropoietin (Roche, Basel, Switzerland) was used at a concentration 
of 1 U/ml. Anti-pY694-STAT5 (#9351, Cell Signaling, Berverly, USA) and anti-GFP (600-101-215, Rockland, 
Gilbertsville, USA) were used for immunoblotting. Anti-rabbit and anti-goat antibodies conjugated to horserad-
ish peroxidase (HRP) were ordered from, DAKO (Glostrup, Denmark).
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Plasmid constructs. The cDNA of murine STAT5A was either cloned into pLentiLox (Vector Core, University 
of Michigan, USA) or pcDNA3.1 (Invitrogen, Paisley, UK) expression vectors and fused to the cDNA of the 
enhanced yellow fluorescent protein (eYFP). The cDNA of the human erythropoietin receptor (EpoR) was cloned 
into the pcDNA5/FRT/TO expression vector and fused to the cDNA of the hemagglutinin tag (HA). Fluorescent 
proteins were fused to the C-terminus of the target proteins, whereas the HA-tag was fused to the N-terminus 
of the human EpoR. Point mutants of STAT5A were generated with PCR based QuikChange® XL Site-Directed 
Mutagenesis Kit according to manufacturer’s instructions (Agilent Technologies, Santa Clara, CA, USA).
Cell culture, transfection and inducible cell lines. HeLa T-Rex (Invitrogen, Paisley, UK) cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM)/GlutaMAX (Gibco, Paisley, UK). Transient transfection 
of HeLa T-REx cells was performed using Trans IT® -LT1 (Mirus, Madison, USA) according to manufacturer’s 
instructions. Stable transfection of HeLa T-Rex cells for the inducible expression of HA-EpoR was performed 
with the Flp-In system (Invitrogen, Paisley, UK) using 250 μ g/ml hygromycin B (PAA, Austria) and 15 μ g/ml 
blasticidin (Invitrogen, Toulouse, France) for selection. The expression of HA-EpoR was induced with 5 ng/ml 
doxycycline (Sigma, St. Louis, USA) for 24 h. All media were supplemented with 10% FCS (Life Technologies, 
Darmstadt, Germany) and 25 U/ml penicillin/streptomycin (Lonza, Verviers, Belgium). Cells were incubated at 
37 °C in a water-saturated atmosphere with 5% CO2. Phosphatase inhibition was carried out by sodium vanadate 
(Na3VO4) treatment (1 mM) for 2 h.
Lentiviral mediated stable transduction. To achieve stable and constitutive expression of STAT5A con-
structs in inducible HeLa T-Rex cells, self-inactivating lentiviral constructs were used according to the guide-
lines of the RNAi consortium. Briefly, the cDNA of STAT5A-eYFP and the point mutants of STAT5A-eYFP 
were cloned into the lentiviral pLentiLox expression vector downstream of the CMV promotor (Vector Core, 
University of Michigan, USA). HEK293-T packing cells were seeded on 6-cm dishes on to be 80–90% confluent 
at the time of transfection. On the second day, HEK293-T cells were transiently co-transfected with the lentiviral 
vector, psPAX2 (packing plasmid) and pMD2.G (envelope plasmid). Eighteen hours after transfection the culture 
medium was replaced by high serum growth medium containing 30% FCS. Viruses were harvested 24 hours after 
medium exchange. For the infection of HeLa T-Rex cells, virus-containing supernatant was supplemented with 
8 μ g/ml polybrene (Sigma, St-Louis, USA) prior to infection.
Preparation of cell lysates, SDS-PAGE and immunoblotting. HeLa T-REx cells were washed with 
PBS (137 mM NaCl, 2.5 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, adjusted to pH 7.4) once and lysed with 
RIPA lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM NaF, 15% 
glycerol) supplemented with phosphatase/protease inhibitors (1 mM Na3VO4, 0.5 mM EDTA, 0.25 mM phen-
ylmethylsulfonylfluoride (PMSF), 5 μ g/ml aprotinin, 2.5 μ g/ml leupeptin) according to standard procedures. 
The proteins were separated by SDS-PAGE and transferred to a PVDF membrane with subsequent immuno-
detection using specific antibodies. Primary and HRP-conjugated secondary antibodies were diluted in TBS-N 
buffer (20 mM Tris–HCl, pH 7.5, 135 mM NaCl, 0.1% Nonidet P-40). Membrane-bound antibody complexes were 
detected by chemiluminescence (ECL, Millipore, Billerica, MA, USA).
Blue Native PAGE and detection of enhanced YFP. Dimerization of fluorescently eYFP-labeled 
STAT5A constructs was analyzed in HeLa T-REX HA-EpoR cells. Cell lysis was performed under native condi-
tions using the lysis buffer of the NativePAGETM Sample Prep kit (Invitrogen Paisley, UK) supplemented with 
2% digitonin (Sigam, St.Louis, USA). The lysates were cleared by centrifugation and incubated with Coomassie 
brilliant blue G-250 and separated over night at 4 °C using NativePAGETM Bis-Tris gel system with a gradient 
polyacrylamide gel (4–16%) according to the manufacturer’s instructions. Dimerization of STAT5A-eYFP con-
structs was analyzed by detection of the eYFP fluorescence with a typhoon fluorescence scanner (GE Healthcare, 
Germany) by excitation with a 488 nm laser line. The emission was detected using a 515–555 nm bandpass filter.
Peptide precipitation assay. Transiently transfected HeLa T-REx parental cells were lysed with storage 
buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 0.1 mM EDTA, 10% glycerol, 0.5% Nonidet P-40) supplemented 
with phosphatase/protease inhibitors. Lysates were cleared by ultracentrifugation (100.000 g, 30′ , 4 °C). Peptides 
corresponding to the phosphotyrosine motif of STAT5 (b-tat-AKAVDGpYVKPQIKQVVPEFVNASADAG-a) 
were synthesized with > 95% purity, modified by N-terminal biotinylation (b-) and C-terminal amidation (-a) 
and contain the HIV tat protein derived GRKKRRQRRRPQ (tat) sequence at the N-terminus. 25 nmol of the 
peptides were coupled to NeutrAvidin Agarose Resin (Thermo Scientific, Pittsburgh, PA, USA) for 2 h at 4 °C, 
washed twice with storage buffer and incubated with 1 mg of the lysate over night at 4 °C. Peptide/protein com-
plexes were washed 3 times with storage buffer for 10 minutes and the precipitates were analyzed by SDS-PAGE 
and immunoblotting.
Fluorescence microscopy. HeLa T-REx cells expressing fluorescently labeled fusion proteins were grown 
on glass cover slips. After paraformaldehyde (3.7%) fixation cells were stained with DRAQ5 (Biostatus, UK) and 
Phalloidin-Atto 550 (Sigma, St. Louis, USA) to label nuclei and actin, respectively. Cover slips were mounted 
with ImmuMount (Thermo Scientific, Pittsburgh, PA) as has been described previously55. Fluorescence images of 
adherent cells were generated with a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Germany), using the Zeiss 
LD C-apochromat 40x/1.1 water objective. Images represent confocal slices of approximately 1 μ m and were ana-
lyzed with the ZEN 2012 software (Zeiss, Jena, Germany).
Information on statistics and sample numbers is given in the corresponding figure legends.
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